Search bioRxiv⌕ Search

bioRxiv · 10.1101/2023.03.01.529424

AKI and CKD Worsen Outcomes in Experimental Sepsis: Creating a Reverse-translational Model of Acute Peritoneal Infection and Recovery in an Immunocompromised Host.

Abstract

IntroductionInfection is a leading cause of morbidity and mortality in individuals with kidney disease. Both acute kidney injury (AKI), and chronic kidney disease (CKD) are clinical states that have been associated with higher risk of incident infection, and poor outcomes once infection has been established. A variety of host-and pathogen-specific factors are implicated as potential causes for these disparate outcomes including an altered host microbiome, innate and adaptive immune defects, and poor renal clearance and cytokines. However, there remains significant difficulty in modeling both human kidney disease and infection into an animal host. Likewise, there remains a poor understanding of the mechanisms underlying the unique immunodeficiency imparted by AKI and CKD, and if either condition imparts disparate risk. MethodsC57BL/6J mice were given vehicle or aristolochic acid (AA) to create AKI (control, AKI groups) or CKD (control, CKD groups). Donor mice from all four groups underwent sterile cecal dissection and creation of cecal slurry (CS) preparations, which was later injected into separate mice in a matched host-recipient manner, at either high or lower doses. Animals were clinically monitored for either 24- or 72-hours after inoculation, then euthanized. Animal survival, sepsis severity, temperature, weights, and transcutaneous glomerular filtration rate (tGFR) were tracked longitudinally throughout the study. Histology for kidney injury, peripheral blood flow cytometry for leukocyte counts, plasma cytokines, and typical markers for organ injury were determined. ResultsCompared to controls, animals with AKI experienced much more severe sepsis across virtually all tracked metrics, and no animals with AKI survived high-dose CS injection past 24-hours. AKI mice manifested with a peripheral defect in leukocytes early after sepsis, with severe and persistent cytopenias, and a dramatically heightened early pro-inflammatory cytokine response. Septic CKD mice also had worse outcomes than controls, though less severe, and occurring later than in animals with AKI. Interestingly, animals with AKI had worse clinical outcomes and evidence of organ injury than mice with CKD at any dose or time-point after inoculation, despite a higher mean baseline measured GFR. ConclusionsRodents with established AKI and CKD experience worse clinical outcomes and organ injury versus controls in a CS model intraperitoneal live-bacterial infection. Additionally, mice with AKI experienced earlier and more severe morbidity and mortality than animals with CKD.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Floyd, D., Colbert, J. R., Furgeson, S. B., Montford, J. R.. 2023-03-02. AKI and CKD Worsen Outcomes in Experimental Sepsis: Creating a Reverse-translational Model of Acute Peritoneal Infection and Recovery in an Immunocompromised Host.. https://doi.org/10.1101/2023.03.01.529424

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Ksp37 is a rapidly mobilized NK cell secretory protein that engages FGF2

A key feature of natural killer (NK) cells is their preloaded arsenal of effector molecules, allowing them to rapidly respond upon activation. In this study, we characterized a previously unexplored secretory protein, termed killer-specific secretory protein of 37 kDa (Ksp37), which is highly abundant in differentiated CD56dim NK cells. Ksp37 is rapidly secreted in a dose-dependent and JAK-1 dependent manner upon low levels of cytokine stimulation, making it a sensitive readout for NK cell activation. Following secretion, intracellular levels were rapidly replenished, preserving responsiveness to subsequent cytokine stimulation. We found that Ksp37 is stored in polarized intracellular compartments distinct from those containing canonical cytotoxic effector molecules, including granzyme B and perforin, which require stronger stimulation for release. Lastly, we identified Ksp37 as a novel binding partner of fibroblast growth factor 2 (FGF2). This opens new avenues of exploration for the role of NK cells in remodeling their extracellular environment by modulating the FGF2-FGFR1 axis, which plays a key role in tumor growth, angiogenesis and tissue repair.

immunology↗

ACE-engineered human iPSC-derived neutrophils enhance host defense against multidrug-resistant bacterial infections

Severe neutropenia predisposes patients to life-threatening infections, while donor-dependent granulocyte transfusions are limited by availability and variable cell quality. Here, we engineered human induced pluripotent stem cells (iPSCs) to constitutively or inducibly express angiotensin-converting enzyme (ACE) and differentiated them into functional ACE-engineered neutrophils (ACE-iNeu). ACE expression enhanced granulocytic maturation, reactive oxygen species generation, inflammatory cytokine production, and antimicrobial signaling. ACE-iNeu exhibited enhanced bactericidal activity against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. Following adoptive transfer into neutropenic mice, ACE-iNeu significantly reduced circulating and tissue bacterial burdens. Integrated metabolomic and transcriptomic analyses revealed ACE-associated alterations in adenine nucleotide abundance and developmental and inflammatory pathways. Together, these findings establish ACE engineering as a strategy to enhance the production and antimicrobial function of human iPSC-derived neutrophils and support further preclinical development of engineered granulocyte therapies for severe drug-resistant infections.

immunology↗

Tetravalent dengue mRNA vaccination orchestrates balanced four-serotype immunity with durable memory and protection in mice.

An effective dengue vaccine must establish durable immunity across four dengue virus (DENV) serotypes, evade antibody-dependent enhancement (ADE), and overcome immune imprinting from prior exposure. Here, we developed TetprM-E mRNA-LNP, a tetravalent vaccine comprising LNP-formulated nucleoside-modified mRNAs encoding DENV1-4 precursor membrane-envelope (prM-E) antigens, and evaluated its immunogenicity, durability, protection and breath across serotype-specific immune backgrounds. Three immunization strategies elicited neutralizing titers greater than 1:1500 against each serotype. Passive transfer of immune sera conferred 100% survival and reduced viremia after lethal DENV2 challenge in immunocompromised mice. Vaccination induced DENV envelope (env)-specific CD8+T cells and CD4-dependent germinal-center responses. DENV env-binding antibodies persisted for 34 weeks alongside DENV env-specific memory B cells. Vaccine-elicited sera showed no measurable in vitro ADE. Although monovalent priming initially biased antibody responses, TetprM-E mRNA-LNP vaccination broadened neutralization across DENV1-4 regardless of priming serotype. Together, TetprM-E mRNA-LNP elicits broad, durable, and protective immunity despite serologic constraints from pre-existing immunity.

immunology↗